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Congenital myasthenic syndromeDisorders affecting the presynaptic, synaptic, and postsynaptic portions of the neuromuscular junction arise from
variousmechanisms in children and adults, including acquired autoimmune or toxic processes as well as genetic
mutations. Disorders include autoimmune myasthenia gravis associated with acetylcholine receptor, muscle
speciﬁc kinase or Lrp4 antibodies, Lambert–Eaton myasthenic syndrome, nerve terminal hyperexcitability syn-
dromes, Guillain Barré syndrome, botulism, organophosphate poisoning and a number of congenital myasthenic
syndromes. This review focuses on the variousmolecular and pathophysiologicalmechanisms of these disorders,
characterization ofwhich has been crucial to the development of treatment strategies speciﬁc for each pathogen-
ic mechanism. In the future, further understanding of the underlying processes may lead to more effective and
targeted therapies of these disorders. This article is part of a Special Issue entitled: Neuromuscular Diseases:
Pathology and Molecular Pathogenesis.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Diseases of the neuromuscular junction (NMJ) (Table 1) produce
weakness which generally varies with repeated synaptic ﬁring, i.e.
sustained or repeatedmuscle contraction [1–3]. The “true”myasthenias
are NMJ disorders in which weakness worsens with sustained muscle
contraction or work and improves with rest. Analysis of these diseases
has determined that they primarily involve components of the postsyn-
aptic portion of the NMJ. The other disorders of the NMJ result in weak-
ness that either improves or remains unchanged with exercise. The
latter group is associatedwith dysfunction of the presynaptic apparatus
or of the components of the synaptic cleft. The clinical characteristics of
the “fatiguing”weakness in an individual patient with one of the “true”
myasthenias can be conﬁrmed electrophysiologically by decrementing
compound muscle action potentials (CMAPs) in response to slow rates
of motor nerve stimulation (2–3 Hz), in association with normal ampli-
tudes of the responses to single nerve stimuli. In contrast, most of the
presynaptic NMJ disorders are associated with reduced amplitudes of
the CMAPs in response to singlemotor nerve stimuli but with increased
amplitudes following rapid stimulation of the nerve.
Themajority of patients with NMJ dysfunction have eithermyasthe-
nia gravis (MG) or Lambert–Eaton myasthenic syndrome (LEMS) [4,5].
Remarkably, both diseases are autoimmune in nature and, moreover,
each results from a T cell-directed antibody (Ab)-mediated attack onuscular Diseases: Pathology and
University of California, Davis,ion channels that are crucial for neuromuscular transmission (NMTx)
via theNMJ. ForMG, the target of the auto-Ab attack is the nicotinic ace-
tylcholine receptor (AChR) in the postsynaptic membrane, whereas for
LEMS the target is the P/Q-type voltage-gated calcium channel (VGCC)
located in the presynaptic motor nerve terminal membrane. In a third
disorder, autoimmune neuromyotonia, Ab-mediated attack on the
nerve terminal (rectifying) voltage-gated potassium channel results in
spontaneousﬁring of the synapse [6]. In Guillain Barré syndromeAbs di-
rected against gangliosides GM1 and GQ1b have been shown to affect
NMTx at the NMJ in addition to demyelinating and axonal nerve dam-
age. The reasons for the particular susceptibility of the NMJ to autoim-
mune attack have not yet been elucidated. Nonimmune diseases also
lead to disordered NMTx. Organophosphate poisoning results in block-
ade of themuscle acetylcholinesterase, leading toNMJ dysfunction from
excessive neurotransmitter activity. In botulism, the various toxins bind
to and hydrolyze individual intracellular presynaptic proteins involved
in docking and release of (acetylcholine (ACh)-containing vesicles. In
addition, over the last twenty years or so, a group of genetically deter-
mined congenital myasthenias have been identiﬁed and studied. Each
congenital myasthenic syndrome (CMS) results from a mutation in a
protein important to NMTx. The mutations have been classiﬁed as to
whether they involve presynaptic, synaptic cleft or postsynaptic
proteins [7].
2. Review of NMJ structure and function
The NMJ is the most highly studied neural synapse—primarily be-
cause of its location in the peripheral nervous system isolated from
Table 1
Features of various neuromuscular junction disorders. NMJ = neuromuscular junction, AChR = acetylcholine receptor, MuSK = muscle speciﬁc receptor tyrosine kinase, Lrp4 =
lipoprotein receptor-related protein 4, LEMS = Lambert-Eaton myasthenic syndrome, VGCC = voltage gated calcium channel, VGKC = voltage gated potassium channel, CMS =
congenital myasthenic syndrome.
NMJ disorder
Autoimmune MG
AChR MG
MuSK-MG
Lrp4-MG
LEMS
Acquired peripheral nerve
Hyper excitability syndromes
Guillain–Barre syndrome
Botulism
Organophosphate Poisoning
CMS
Synaptic location
Postsynaptic
Postsynaptic
Postsynaptic
Presynaptic
Presynaptic
Presynaptic
Presynaptic
Synaptic deft
Presynaptic, synaptic
deft or postsynaptic
Autoantibody
Nicotinic AChR
MuSK
Lrp4
P/Q type VGCC
VGKC
GM1, GQ1b
–
–
–
Protein(s) involved Thymic abnormalities
–
–
–
–
– –
– –
–
–
–
BoNT toxin and SNARE proteins
Acetylcholinesterase
Various mutated proteins
Lymphoid hyperplasia
and thymoma
–
–
Unknown
Unknown Unknown
Age at onset (years)
20–30 (women) and > 50 (men)
Variable
> 40 (limited data)
40–60 (usually related to lung
carcinoma)
Bimodal (adult and childhood)
Neonates and all other ages affected
–
Predominanantly in childhood
Female : male
ratio
1:2 (3:1 in
juvenile MG)
8.5:1
2.5:1
1:1
1:1.25
–
–
–
Fig. 1. Schematic of the neuromuscular Junction. VGSC = voltage-gated Na channel,
VGKC = voltage-gated potassium channel, VGCC = voltage-gated calcium channel,
AChE = acetylcholinesterase. Adapted from Vincent A, Newland C, Croxen R, Beeson D.
Genes at the junction—candidates for congenital myasthenic syndromes. Trends Neurosci
1997; 20(1):15–22. Adapted with permission.
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source of its close analog within the electric organs of electric ﬁsh. The
information on the biology of the NMJ has assisted in the analysis of a
series of diseases that affect its function resulting in motor weakness.
The NMJ begins to form when the axon growth cone of a developing
motor neuron, or a sprouting motor axon, encounters a developing
myotube, or a denervated muscle ﬁber, and begins to secrete agrin, a
glycoprotein with a laminin-binding domain that anchors it to the ex-
tracellular matrix [8–11]. Agrin can initiate the formation of the NMJ
but requires the presence of the postsynaptic transmembrane kinase,
muscle-speciﬁc kinase (MuSK). The latter is a receptor tyrosine kinase
that, when activated by agrin, self-phosphorylates and phosphorylates
a number of other proteins important to the formation of the NMJ,
mediated through various downstream signal transduction pathways.
The agrin/MuSK interaction requires mutual binding to a third trans-
membranemuscle protein, the low density lipoprotein receptor-related
protein 4 (Lrp4) [12–15]. This process induces dense clustering of the
AChRs in the postsynaptic membrane and marked folding and speciali-
zation of that membrane [8–11,16,17]. A number of less well under-
stood processes also occur in the postsynaptic region, referred to as
themuscle endplate (EP), that lead to: 1) secretion of acetylcholinester-
ase into the extracellularmatrix, 2) concentration of sodium channels in
themembrane of the valleys of the postsynaptic folds and 3) retrograde
release of factors that induce the axon terminal to develop the speciali-
zations involved in activity-induced release of neurotransmitter (ACh)-
containing synaptic vesicles. The mature NMJ (Fig. 1) consists of the
specialized nerve terminal of themotor axon, which, when depolarized
by an action potential, releases the ACh into the synaptic cleft. The re-
leased ACh diffuses across the cleft to bind to the very tightly packed
AChRs located on the peaks of the highly folded EP membrane. The
AChR is a multi-subunit transmembrane ligand-gated ion channel that
opens upon binding of two molecules of ACh, resulting in cation inﬂux
and depolarization of the muscle membrane. When the depolarization
reaches threshold, an action potential is initiated in the sodium
channel-rich valleys of the synaptic folds leading to muscle contraction.
3. MG subgroups
Several subgroups of MG have been identiﬁed on the basis of clinical
presentation, autoAb proﬁle and thymic pathology including: early-
onset (before age 40) MG, late-onset MG and thymoma associated-
MG. Early-onset MG generally begins with ocular muscle weakness
followed by generalized weakness and occurs more often in female
patients. There is an association with HLA-B8DR3 and thymichyperplasia [18]. In contrast, late-onset MG is more common in males
over 60 years of agewithout thymoma [19]. There is no apparent gender
predilection; however, compared to early-onset MGwithout thymoma,
weakness including oropharyngeal involvement appears to bemore se-
vere and associated with additional autoAbs, including titin Abs [20],
paraneoplastic Abs, voltage-gated K+ and Ca2+ channel Abs, Hu Abs,
DHP related protein 5 and GAD Abs [21].
4. Role of the thymus in MG
Although the factors involved in the induction of autoimmune MG
have not been fully elucidated, the association ofMGwith abnormalities
of the thymus was described by Weingart as early as 1901. Approxi-
mately 10% of patients with autoimmune MG have a thymoma, which
may possibly play a role in disease initiation through multiple mecha-
nisms including the expression of self-antigens by thymoma cells and
impaired negative selection of autoreactive T lymphocytes. Another
60% of patients have thymic hyperplasia, deﬁned by the presence of
medullary lymphoid follicles and germinal centers. While a body of ev-
idence exists [22] that thymectomy produces long-term beneﬁt in MG,
the ﬁrst randomized controlled clinical trial of this treatment is current-
ly in progress.
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(AChR-MG)
Approximately ninety percent of patients with generalized acquired
myasthenia have measurable AChR Abs circulating in blood (usually re-
quiring the use of human AChR for the assay). For many years MG had
been suspected to be an autoimmune disorder of the NMJ. Strong sup-
port of this hypothesis, as well as the identiﬁcation of the autoantigen,
derived from the serendipitous observation by Patrick and Lindstrom
in 1973 that rabbits immunized, in order to obtain Abs, with AChR re-
cently puriﬁed from ﬁsh electric organ, developed weakness and the
electrophysiologic abnormalities similar to those in human MG [23].
This experimental disorder in rabbits, subsequently named experimen-
tal autoimmune myasthenia gravis (EAMG), was reproduced in other
species, especially inbred Lewis rats [24] and also, to a lesser degree,
susceptible strains of mice [25]. Clinical, pharmacological, histological,
electrophysiological and immunological analysis of EAMG led to exten-
sive observations related to the pathogenic mechanisms in this disease,
[26,27]most of which have been found to hold for the human disease as
well [26]. Acutely there is inﬂammatory destruction of the endplate
membrane, whereas chronically the membrane appears to reform in a
simpliﬁed fashion with reduced amounts of AChR [28].
AutoAbs and autoreactive T cells directed against the NMJ AChR are
present in both MG and EAMG. However, the effects at the NMJ are car-
ried out solely by the Abs, which primarily target the alpha 67-alpha76
portion of the alpha subunit of the AChR, known as the main immuno-
genic region (MIR) [29]. The Abs are primarily of the IgG1 and IgG3
isotypes and are thus capable of activating complement [30,31]. Three
effector mechanisms of these Abs have been identiﬁed that result in
clinical symptoms including 1) direct blockade of ACh binding sites
inhibiting the opening of the ion channel, [32] 2) cross-linking of
AChRs by divalent Abs accelerating endocytosis and degradation of
AChRs, referred to as antigenic modulation [33,34] and 3) complement-
mediated damage to the entire muscle endplate via formation of mem-
brane attack complexes [35–37]. While direct binding of the AChR by
Abs in mechanism 1 appears to play a minor role in pathogenesis, the
second and thirdmechanisms result in removal of AChRs leading to clin-
ically observed muscle weakness. In addition, the third mechanism,
complement-mediated endplate membrane lysis, also destroys AChR-
associated proteins required for NMJ function and maintenance.
6. MuSK antibody MG (MuSK-MG)
Patients who lack circulating Abs to AChR are referred to as having
“seronegative MG” and have clinical characteristics that are similar,
but not necessarily identical, to those with AChR Abs, i.e., seropositive
MG. Seronegative patients were reported initially to respond as a
group equally well to the treatments that are effective in seropositive
patients [38]. Early studies demonstrated that IgM from some seroneg-
ativeMGpatients decreased AChR function in culturedmuscle cell lines,
but did not appear to bind directly to AChR [12,15,39]. Vincent et al.
were able to identify an IgG in some patients that bound to an antigen
on muscle cell lines that is distinct from AChR [12]. Further analysis
identiﬁed the target as MuSK. These investigators went on to detect
MuSK Abs in seventy percent of seronegative patients [14]. Larger stud-
ieswith amore precise assayhave determined that theﬁgure is closer to
40 percent of seronegative patients and, to date, such Abs have been
found only in patients with fatigable weakness [13,40–42]. This MuSK
Ab-positive subgroupof seronegative patients hasmany clinical similar-
ities to AChRMG, but tends to differ signiﬁcantly in demonstratingmore
focal involvement than seropositive MG, frequently with severe in-
volvement of neck, shoulder, facial and bulbar muscles, at times with
wasting of these muscles, although there is considerable variability
from patient to patient [40–43]. Also, no MuSK MG patient has been
found to have thymic lymphoid hyperplasia (commonly found in MG)
[44,45]. Very preliminary data suggest other differences, includingobservations that MuSK Ab patients respond especially well to plasma
exchange, more so than to intravenous immunoglobulin [40], and do
not respond to thymectomy [13,40,41]. Additionally, acetylcholine-
esterase inhibitors tend tobe less effective andmay even be counterpro-
ductive [40,41] while Rituximab appears to be more beneﬁcial than in
patients with AChR-MG [46].
MuSK is a 100 kD typical transmembrane receptor tyrosine kinase
with anN-terminal extracellular domain followed by a short transmem-
brane domain and then a C-terminal cytoplasmic domain [47–50]
(Fig. 2). This molecule is crucial to the interaction of muscle with
agrin. MuSK responds by phosphorylating and binding a number of EP
proteins, most importantly rapsyn, an intracellular protein that binds
the intracellular domain of AChR and is likely the motor for dense
AChR clustering [11,51,52]. The extracellular domain of MuSK, which
appears to be required for interactionwith agrin, comprises four immu-
noglobulin (Ig)-like domains. Between Ig-3 and Ig-4 is a cysteine-rich
(frizzled-like) C6 box region [47–49]. The cytoplasmic domain contains
the kinase activity and signaling components of themolecule leading to
the development of the postsynaptic apparatus although binding to
rapsyn appears to require a contribution from the Ig-4 region [53].
Studies employing both rat and human MuSK have determined that it
is only the extracellular domain of the molecule that is the target of
the MuSK-MG Abs [14,54]. These Abs induced in animals by active or
passive immunization produce EAMG that mimics the human disease
[55–58].
MuSK Abs are predominantly of the IgG4 isotype which is unable to
bind complement factor C1q and thus does not cause complement
activation [59]. Additionally, IgG4 undergoes a post-translation modiﬁ-
cation known as “Fab-arm exchange”which involves recombining half-
antibodies with other IgG4 molecules, making them incapable of cross-
linking antigens [60].
7. Lrp4 antibody MG (Lrp4-MG)
Lrp4 has been identiﬁed as a crucial postsynaptic protein for the de-
velopment and maintenance of the neuromuscular junction [61] with
speciﬁc function as the agrin receptor necessary for the activation
MuSK [62,63]. Lrp4 Abs were hypothesized as a pathogenic factor in se-
ronegative MG due to its postsynaptic localization and observations in
Lrp4 null mutant animal models which showed similar phenotype to
that observed in MuSK negative animals. Recent studies have shown
antisera from double-seronegative (negative for AChR Abs and negative
for MuSK Abs) MG patients speciﬁcally bound to HEK293 cells
transfected with human Lrp4 and inhibited binding to agrin [64,65].
The Abs were found to be predominantly of the IgG1 isotype, which is
capable of activating complement and thus producing damage to post-
synaptic membrane folds via the membrane attack complex. Addition-
ally, inhibition of agrin-induced aggregation of AChRs at the
neuromuscular endplate has been implicated as a pathogenic mecha-
nism in Lrp4-MG.
8. Lambert–Eaton myasthenic syndrome (LEMS)
LEMS is an autoimmune disorder affecting presynaptic P/Q-type
voltage-gated calcium channels of the neuromuscular junction causing
impaired quantal release of acetylcholine leading to muscle weakness.
The P/Q-type VGCC is the basis for the action potential-induced Ca++
inﬂux, which triggers fusion of the ACh-containing synaptic vesicles
with the nerve terminal plasma membrane resulting in release of ACh
into the synaptic cleft. Anderson in 1953 ﬁrst described a patient with
muscle weakness and diminished deep tendon reﬂexes with improve-
ment in these symptoms after removal of a small-cell lung cancer [66].
A few years later Eaton and Lambert identiﬁed a series of similar cases
with a distinctive incremental response on repetitive nerve stimulation
[67]. Small-cell lung cancer and autonomic symptoms are common in
LEMS [67,68]. Serum Abs to P/Q-type VGCC, which are present on
Fig. 2. Schematic ofMuSK and associatedmolecules responsible for acetylcholine receptor clustering. AChE, acetylcholinesterase; AcCoA, acetyl coenzyme A; ChAT, choline acetyltransfer-
ase; ColQ, AChE collagen-like tail subunit; Dok-7, downstreamof tyrosine kinase 7; LRP4, low-density lipoprotein receptor-related protein 4;MuSK,muscle-speciﬁc kinase; SNARE, soluble
NSF attachment protein receptor. Adapted from Spillane J, Beeson D, Kullmann D. Myasthenia and related disorders of the neuromuscular junction. J Neurol Nurosurg Psychiatry 2010;
81:850–857. Adapted with permission.
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by radioimmunoassay in 1995 [69,70]. These Abs are felt to be
paraneoplastic in nature and directed at the small-cell lung cancer in a
signiﬁcant number of cases [69,71], though associations with other
cancers including non-small-cell lung cancer, mixed lung carcinomas,
prostate carcinoma, thymoma and lymphoproliferative disorders have
been described [72,73]. The VGCC, like the AChR, is a complex protein
made up of multiple subunits. ELISA and western blotting studies on
the extracellular alpha1 subunit which is responsible for its pore
forming properties have identiﬁed Abs to linker domains II and IV in ap-
proximately 50% of patients with LEMS. Although the antigenic trigger
for the production of anti-VGCC Abs in patients without cancer is un-
known, these cases have been found to have an association with the
HLA haplotype B8 Dr2 DQ2 and other autoimmune diseases [74].
9. Acquired peripheral nerve hyperexcitability syndromes
The acquired peripheral nerve hyperexcitability syndromes include
autoimmune neuromyotonia and cramp-fasciculation syndrome char-
acterized by muscle cramps, weakness, fasciculations and increased
sweating. Approximately 40% of cases have been associated with anti-
voltage gated potassium channel Abs, which are felt to be the main
pathogenic agents. Approximately 20% of cases have been associated
with thymoma [6,75].
10. Guillain Barré syndrome
Guillain Barré syndrome and variants such as Miller Fisher
syndrome are acute inﬂammatory autoimmune neuropathies which
lead to demyelination and axonal damage. Infection by campylobacter
jejuni and other pathogens preceding the onset of symptoms is
common. Molecular mimicry between the infectious agents and gangli-
oside antigens on neural cells is felt to produce a cross-reactive humoral
and cell mediated immune response. Approximately 20–60% of patient
with Guillain Barré syndrome and Miller Fisher syndrome have Abs to
GM1 and GQ1b, which have been shown to bind to gangliosides
expressed in the NMJ and cause complement mediated changes inneurotransmitter release via disruption of the voltage-gated sodium
channels [76–78].
11. Botulism
The anaerobic bacteria clostridium botulinum produces seven dis-
tinct neurotoxins, BoNT-A through BoNT-G, each of which disrupts neu-
rotransmitter release (Fig. 3). The BoNT toxins are initially synthesized
as an inactive single-chain protein and post-translationally modiﬁed
into the active dichain molecule organized into a heavy and light
chain linked by a disulﬁde bond [79,80]. The heavy chains contain bind-
ing and translocation functional domains while the light chains contain
a catalytic zinc-endopeptidase domain which is speciﬁc for one of the
following proteins of the neurotransmitter release apparatus: VAMP/
snyaptobrevin, SNAP-24 and syntaxin 1, the latter two proteins make
up the SNARE (solubleNSF (N-ethylmaleimide-sensitive fusion protein)
family of proteins involved in fusion of synaptic vesicles. A three step
process has been described involving internalization of the BoNT at
the presynaptic nerve terminal by receptor mediated endocytosis [81]
followed by structural changes in the translocation domain which
allow it to form a pore in the endosomemembrane induced by the acid-
ic pH of the endosome. The catalytic domain is then able to translocate
across the endosomemembrane and cleave one of the SNARE proteins,
which prevents neurotransmitter release into the NMJ [82–84].
12. Organophosphate poisoning
Organophosphate compounds are used widely around the globe as
insecticides and as “nerve agents” in chemical warfare. Exposure to
these compounds leads to irreversible inhibition of acetylcholinesterase.
Several syndromes associated with organophosphate poisoning have
been described based on the timing of symptom onset including acute
cholinergic crisis, intermediate syndrome, and organophosphate-
induced delayed neuropathy (OPIDN). Organophosphate compounds
were initially reported to inhibit AChE by Gross et al. in the 1930s [85].
Subsequent studies using diisoprophylﬂourophosphate in horse serum
by Janz et al. showed that themechanism involved the irreversible phos-
phorylation of a serine residue at the hydroxyl group in the active site of
Fig. 3. Schematic of the four stepmechanism of action of clostridial neurotoxins including (1) membrane binding, (2) internalization, (3) translocation and (4) intracellular action. SNAP-
25, synaptosomal-associated protein 25; VAMP, vesicle associated membrane protein; SNARE, soluble NSF attachment protein; BoNT, botulinum neurotoxin; TeNT, tetanus neurotoxin.
Adapted from Lalli G, Bohnert S, Deinhardt K, Verasteugui C, Schiavo G. The journey of tetanus and botulinum neurotoxins in neurons. Trends in Microbiology, 2003; 11(9)431–437.
Adapted with permission.
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Although the mechanism has not been fully elucidated, this reaction
leads to the prolonged accumulation of excess ACh at the NMJ and is
felt to be the cause of failure of neuromuscular transmission.
13. Congenital myasthenic syndromes (CMS)
The CMS are a group of genetically determined diseases resulting
from mutations in genes encoding proteins that are important for neu-
romuscular transmission (Fig. 4). These disorders are characterized by
weakness andmuscle fatigability that usually starts during the perinatalFig. 4. Classiﬁcation and localization of proteins encoded by genes associated with congenital m
syndromes: an update. Cur Opin Neurol. 2013; 26(5):561–568. Adapted with permission.period or infancy. However, symptoms can start at any time in life pos-
ing diagnostic difﬁculties with seronegative myasthenia gravis. The ﬁrst
CMS thoroughly characterizedwas AChE deﬁciency by Andrew Engel in
1977 [87]. Electrophysiological and electron microscopic studies of in-
tercostal and anconeus muscle biopsies were utilized to identify
pre-synaptic vs. post-synaptic mechanisms by which variousmutations
caused CMS [87,88]. Since that time, molecular genetics through the use
of the candidate gene approach, linkage analysis and whole exome se-
quencing has allowed the identiﬁcation of an ever growing number of
disease genes, though a large proportion remain unidentiﬁed [89,90].
Approximately 85% of identiﬁed CMS involve postsynaptic mutationsyasthenic syndromes. Adapted from Hantaï D, Nicole S, Eymard B. Congenital Myasthenic
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ed proteins including RAPSYN, SCN4A, MUSK, DOK7 and PLEC1. The
most commonly mutated gene identiﬁed patients with CMS is the
CHRNE, encoding the epsilon subunit of the AChR. Individual mutations
in this gene can variously result in slow channel syndrome, fast channel
syndrome or AChR deﬁciency [91,92]. AChR deﬁciency CMS is predom-
inantly due to mutations located on the extracellular NH2 terminal re-
gion and in the M3/M4 loop due to missense, frameshfting, splice-site,
nonsense and mico-deletions [92]. Other post-synaptic mutations
have been identiﬁed in the CHRNA1, CHRNB1 and CHRND genes
which can also cause kinetic anomalies including slow and fast channel
CMS. Fast channel syndrome is caused by several different mechanisms
including diminished afﬁnity for acetylcholine, impaired gating efﬁcien-
cy and destabilization of channel kinetics [93]. Mutations involving the
MuSK-Dok-7-Rapsyn pathway as well as SCN4A and PLEC1 genes have
also been described which result in post-synaptic dysfunction of neuro-
muscular transmission [94]. Approximately 10% of CMS have been iden-
tiﬁed as synaptic basal lamina associated CMS such as in the COLQ gene
mutation which results in endplate AChE deﬁciency, mutations in the
LAMB2 gene which results in beta2-laminin deﬁciency and mutations
in the AGRN gene which results in agrin anomalies. An estimated 5%
of CMS are related to presynaptic defects including defects in the resyn-
thesis of ACh due tomutations in choline acetyl-transferase (ChAT) and
paucity of synaptic vesicles with yet unidentiﬁed genetic cause [95].
14. Conclusion
Diseases of the NMJ produce weakness through numerous mecha-
nisms affecting the presynaptic, synaptic, and postsynaptic portions of
the NMJ. Acquired, autoimmune Ab-mediated diseases have been iden-
tiﬁed and recently an ever growing number of genetic mutations have
been identiﬁedwhich cause CMS. Advancements in elucidating themo-
lecular and pathophysiological mechanisms underlying each disease
has allowed for the development of treatment strategies speciﬁc for
each pathogenic mechanism. In the future, advancements in molecular
and genetic techniquesmay allow for greater understanding of NMJ dis-
orders and even more effective and targeted therapies.
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